August 2020 - Corcept Therapeutics

Relacorilant With Nab-paclitaxel: Safety and Activity in Patients With Pancreatic Ductal Adenocarcinoma and Ovarian Cancer

August 7, 2020

Munster et al. • 2019 •

Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients With Endogenous Hypercortisolism

August 3, 2020

Pivonello et al. • 2019 • American Association of Clinical Endocrinologists (AACE) 28th Annual Scientific & Clinical Congress